title: [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].
abstract: In recent years the therapy of metastatic melanoma has been revolutionized from a disease with very few efficient treatment options to one with access to multiple therapies which can impact on patient survival. Two main classes of therapies have been developed: 1. Immunotherapy by immune checkpoint inhibitors and 2. Small molecule inhibitors of the MAPK pathway. Immunotherapies achieved by either inhibition of CTLA-4 or the PD1/PD-Ll axes are impacting the overall survival in an important fraction of patients. In addition, the side effects of these immune therapy approaches require early detection by all the specialists involved as well as early management according to precise guidelines for optimal outcome.
authors.forename: B
authors.initials: B
authors.lastname: Moura
authors.forename: K
authors.initials: K
authors.lastname: Homicsko
authors.forename: G
authors.initials: G
authors.lastname: Berthod
authors.forename: J-P
authors.initials: JP
authors.lastname: Cerottini
authors.forename: D
authors.initials: D
authors.lastname: Guggisberg
authors.forename: O
authors.initials: O
authors.lastname: Gaide
authors.forename: M H
authors.initials: MH
authors.lastname: Maillard
authors.forename: O
authors.initials: O
authors.lastname: Michielin
mesh_terms: D064420:Drug-Related Side Effects and Adverse Reactions / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D015398:Signal Transduction / Q000276:immunology; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D035703:Therapies, Investigational / Q000009:adverse effects; D016896:Treatment Outcome; D014612:Vaccines / Q000009:adverse effects
chemical_list: D014612:Vaccines